GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.

ABSTRACT:

Aims

A common, functionally significant polymorphism in GRK5 (Gln41Leu) encodes a gain-of-function enzyme that enhances desensitization of the beta(1)-adrenergic receptor. GRK5 Leu41 has been postulated to confer endogenous 'genetic beta-blockade' and contribute to an attenuated response to beta-blockers in black subjects. The effects of this GRK5 variant on sensitivity to a beta-blocker have not been studied in humans. We hypothesized that the GRK5 Gln41Leu variant contributes to interindividual variability in response to beta-blockade and to the ethnic difference in sensitivity between black and Caucasian individuals.

Materials & methods

We measured the heart rate at rest and during a graded incremental exercise in 154 healthy subjects (85 white and 69 black) before and af

SUBMITTER: Kurnik D 

PROVIDER: S-EPMC2820245 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature